Latanoprost Sifi (Latanoprost)

• Latanoprost is a prostaglandin analog used to lower intraocular pressure in glaucoma and ocular hypertension.
• Primary open‑angle glaucoma: reduces intraocular pressure and helps slow disease progression.
• Ocular hypertension: lowers intraocular pressure to prevent conversion to glaucoma.
• Secondary open‑angle glaucoma (e.g., pseudoexfoliative): provides pressure‑lowering effect similar to primary disease.

• Latanoprost binds to prostaglandin F‑type receptors in the ciliary body, activating a cascade that remodels the extracellular matrix of the uveoscleral pathway. This increases aqueous humor outflow through the uveoscleral route, thereby reducing intraocular pressure and helping to control glaucomatous damage.

Latanoprost may cause ocular and peri‑ocular changes after administration.

Common Side Effects

• Eye redness or hyperemia
• Increased eyelash length and thickness
• Darkening of the iris pigment
• Eye irritation or foreign‑body sensation
• Blurred vision shortly after instillation
• Mild ocular discomfort

Serious or Rare Side Effects

• Severe allergic reaction (e.g., angio‑edema, anaphylaxis)
• Uveitis or intraocular inflammation
• Corneal edema or keratitis
• Paradoxical increase in intraocular pressure
• Macular edema, especially in diabetic patients
• Endophthalmitis or infectious ocular complications

Before using Latanoprost, patients should be informed of important safety considerations.

• Monitor intraocular pressure regularly: ensure therapeutic effect and detect paradoxical rise.
• Avoid use in active ocular inflammation: may exacerbate uveitis.
• Caution in patients with a history of herpetic eye disease: risk of reactivation.
• Inform patients about possible cosmetic changes (iris darkening, eyelash growth).
• Do not use concurrently with other prostaglandin analog eye drops: increased risk of side effects.
• Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents, requiring attention to avoid reduced efficacy or heightened adverse effects.

Major Interactions (Avoid)

• Concurrent use with other prostaglandin analog eye drops: additive ocular side effects.
• Use after recent ocular surgery: may delay wound healing.
• Combination with topical ocular steroids: can diminish pressure‑lowering effect.

Moderate Interactions (Monitor Closely)

• Co‑administration with beta‑blocker eye drops: may produce excessive intraocular pressure reduction.
• Use with carbonic anhydrase inhibitor eye drops: additive pressure‑lowering effect, monitor IOP.
• Contact lens wearers: lenses may retain drug, altering absorption.
• Systemic medications affecting prostaglandin pathways (e.g., NSAIDs): monitor for altered response.